Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$2.72 - $9.4 $40,283 - $139,214
-14,810 Closed
0 $0
Q3 2022

Oct 13, 2022

BUY
$2.55 - $3.89 $37,765 - $57,610
14,810 New
14,810 $0

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.24B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Pvg Asset Management Corp Portfolio

Follow Pvg Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pvg Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Pvg Asset Management Corp with notifications on news.